GlassScriptPhysician profile
Jeffrey H Port
NPI 1285635987
$1,975.00
in general payments reported to CMS, 2019-2025
20 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $262 · 2021: $120 · 2022: $233 · 2023: $182 · 2024: $340 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $420.24 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $261.72 | 2019-2025 | Entyvio, Gattex |
| Abbvie INC. | $250.49 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $199.76 | 2019-2023 | Dificid, Zinplava |
| Gilead Sciences, INC. | $132.66 | 2019-2023 | |
| Pinnacle Biologics, INC | $115.81 | 2024 | Photofrin |
| Mauna Kea Technologies, INC. | $109.82 | 2019-2022 | |
| Pfizer INC. | $109.47 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.18 | 2019-2023 | Trulance |
| Qol Medical, LLC | $78.78 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $38.24 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $29.98 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $23.68 | 2025 | Vowst |
| Shire North American Group INC | $19.16 | 2019 | |
| Redhill Biopharma INC. | $18.77 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.21 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $17.72 | 2022 | |
| Daiichi Sankyo INC. | $15.15 | 2019 | |
| Braintree Laboratories, INC. | $11.09 | 2019 | |
| Olympus America INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Port listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.